Forget About Life Technologies Corp. (LIFE), Check out This Stock

Page 1 of 2
The big news in the medical service and device sector is the speculated buyout of Life Technologies Corp. (NASDAQ:LIFE). However, I believe investors could snatch up Agilent Technologies Inc. (NYSE:A) for a “good” price amid the hype surrounding Life.
Agilent provides bio-analytic and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries, meaning it has a bit more of a diversified portfolio, serving not only the life sciences sector, but a number of other fast growing industries.
Only 25% of Agilent’s revenues come from the Life Sciences segment, with the majority (50%) coming from its Electronic Measurement segment, which includes test products, from general purpose instruments to semiconductor and board test solutions, as well as communications test products and services for wireless communications.
The company also has a diversified end market, where its top markets are industrial (21% of revenues), communications (18%) and pharma/biotech (14%).
However, MarketResearch.com is expecting that the “life science tools” market will generate $80 billion by 2016, on the back of innovation and high-end technologies in new applications. Agilent is making strides to become more active in the health care research market, with its acquisition of scientific instruments maker Varian, which is part of management’s strategy of converting the company to a bio-analytical measurement giant.
China is emerging as a major driver for the company, mainly because of its position as a manufacturing destination. Agilent makes test equipment required by manufacturers, which makes China a key market given China has been a prime location for manufacturing operations.
Other notable opportunities in China include the fact that concerns are being raised regarding food safety and testing, which should further boost food safety equipment demand.
Life Technologies Corp. (NASDAQ:LIFE)Although robust research and development and acquisition-related spending might put pressure on its margins and bottom line in the interim, it has historically done well to capitalize on these, with a 5-year average return on investment of 11.7% and a current return on equity of over 20%. Healthcor Management and Greenhaven Associates were two of Agilent’s largest hedge fund owners going into 2013 (check out all the hedge funds owning Agilent).
Major comps

PerkinElmer, Inc. (NYSE:PKI)’s 
two major segments include Human Health (accounting for 49% of sales) and Environmental Health (51%). Human Health includes genetic screening, medical imaging and bio-discovery, while Environmental Health includes analytic sciences, lab services and safety services.
PerkinElmer’s international expansion has helped it grow sales more than 10% the last ten consecutive quarters through the third quarter of 2012, before moderating to 4% growth during the fourth quarter of 2012. Its fall in 4Q 2012 sales growth was due to a high-single digit decline in Europe sales. As a result, PerkinElmer has guided for 2013 sales growth of between 4% and 6% as emerging markets (30% of sales) continue to cancel out European weakness.

Going into 2013 there were 27 hedge funds long the stock, a 7% decline from the previous quarter. Its top hedge fund owners failed to include any top-name billionaire hedge fund managers, with Robert Joseph Caruso’s Select Equity Group having the most valuable position and Chuck Royce of Royce & Associates a close second (check out other hedge funds loving PerkinElmer).

The Wall Street Journal has reported that private equity firms, including Blackstone and the Carlyle Group, plan to put in a bid for Life Technologies Corp. (NASDAQ:LIFE), and the big news was reports claiming that Thermo Fisher Scientific Inc. (NYSE:TMO) had already submitted a bid. Credit Suisse had previously noted that it could take upwards of $75 per share to get the deal done, thus, Life might still be too cheap (see why).
Life’s portfolio includes systems, instruments, software and custom services for making bio-discovery research techniques more effective and efficient for pharmaceutical and biotech. However, there are a number of competitors in its life sciences market. Its recent high-profile launch of the Ion Proton system is also seeing an influx of competition from other players in the DNA sequencing market. Illumina plans to launch its HiSeq 2500 in the fourth quarter of 2012, and Oxford Nanopore Technologies’s MinION (a disposable DNA sequencing device the size of a USB memory stick) is in the queue.
Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!